Hunan Jiudian Pharmaceutical completes significant share repurchase

Hunan Jiudian Pharmaceutical Co. announced the latest progress in its share repurchase program, approved by the board on February 17, 2025. The company intends to repurchase shares using its own funds and dedicated loan capital for future equity incentive plans, with a total value not less than RMB 100,000,000 and not exceeding RMB 150,000,000. The repurchase price per share will not exceed RMB 24.98.

As of November 30, 2025, Hunan Jiudian Pharmaceutical had cumulatively repurchased 6,180,800 shares through its dedicated securities account via centralized bidding. This represents 1.24% of the company's current total share capital. The highest price paid per share was RMB 18.44, and the lowest was RMB 14.51, with a total transaction amount of RMB 100,031,244 (excluding transaction fees). This repurchase aligns with the company's approved plan and relevant regulations.

The company confirms that the timing, volume, and transaction prices of the repurchases comply with the "Shenzhen Stock Exchange Self-Regulatory Guidelines No. 9—Share Repurchase." Hunan Jiudian Pharmaceutical will continue to advance the repurchase efforts within the designated period, adapting to market conditions, and fulfilling disclosure obligations.